粘附分子档案 - CRB Discovery,LKT/BI-6727/B3300/10 mg
- Description
- Product Info
- Shipping and Storage
- Downloads
- References
Description
BI-6727 is a polo-like kinase 1 (PLK1) inhibitor that exhibits anticancer activity. In vitro, BI-6727 induces apoptosis in acute myelogenous leukemia (AML) cells. This compound is currently in clinical trials as a potential treatment for several cancers; it improves response and survival rates.
Product Info
755038-65-4 |
≥99% |
C34H50N8O3 |
618.81 |
BI6727, Volasertib |
White to off white powder |
Shipping and Storage
-20°C |
Ambient |
Downloads
B3300 Info Sheet PDF |
References
Münch C, Dragoi D, Frey AV, et al. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leuk Res. 2015 Jan 28. [Epub ahead of print]. PMID: 25697066.
Gjertsen BT, Schöffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 2015 Jan;29(1):11-9. PMID: 25027517.
Lin CC, Su WC, Yen CJ, et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer. 2014 May 13;110(10):2434-40. PMID: 24755882.
本文链接： https://www.ebiomall.cn/b117-discovery/info-1518165385.html
